Relay Therapeutics, Inc. (RLAY)
RLAY Stock Price Chart
Explore Relay Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze RLAY price movements and trends.
RLAY Company Profile
Discover essential business fundamentals and corporate details for Relay Therapeutics, Inc. (RLAY) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
16 Jul 2020
Employees
259.00
Website
https://www.relaytx.comCEO
Sanjiv K. Patel
Description
Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
RLAY Financial Timeline
Browse a chronological timeline of Relay Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.41, while revenue estimate is $960.00k.
Earnings released on 5 May 2026
EPS came in at -$0.41 falling short of the estimated -$0.35 by -17.14%, while revenue for the quarter reached $3.00m , missing expectations by -46.24%.
Earnings released on 26 Feb 2026
EPS came in at -$0.32 surpassing the estimated -$0.38 by +15.79%, while revenue for the quarter reached $7.00m , beating expectations by +40.96%.
Earnings released on 6 Nov 2025
EPS came in at -$0.43 falling short of the estimated -$0.39 by -10.26%.
Earnings released on 7 Aug 2025
EPS came in at -$0.41 surpassing the estimated -$0.49 by +16.33%, while revenue for the quarter reached $677.00k , beating expectations by +4.64k%.
Earnings released on 5 May 2025
EPS came in at -$0.46 surpassing the estimated -$0.50 by +8.00%, while revenue for the quarter reached $7.68m , beating expectations by +104.09%.
Earnings released on 26 Feb 2025
EPS came in at -$0.45 surpassing the estimated -$0.57 by +21.05%.
Earnings released on 6 Nov 2024
EPS came in at -$0.63 surpassing the estimated -$0.77 by +18.18%.
Earnings released on 6 Aug 2024
EPS came in at -$0.69 surpassing the estimated -$0.73 by +5.48%.
Earnings released on 2 May 2024
EPS came in at -$0.62 surpassing the estimated -$0.70 by +11.43%, while revenue for the quarter reached $10.01m , beating expectations by +33.26k%.
Earnings released on 22 Feb 2024
EPS came in at -$0.67 surpassing the estimated -$0.76 by +11.84%, while revenue for the quarter reached $1.00k , missing expectations by -99.23%.
Earnings released on 2 Nov 2023
EPS came in at -$0.54 surpassing the estimated -$0.83 by +34.94%, while revenue for the quarter reached $25.20m , beating expectations by +6.71k%.
Earnings released on 8 Aug 2023
EPS came in at -$0.81 falling short of the estimated -$0.78 by -3.85%, while revenue for the quarter reached $119.00k , missing expectations by -84.13%.
Earnings released on 4 May 2023
EPS came in at -$0.78 falling short of the estimated -$0.70 by -11.43%, while revenue for the quarter reached $226.00k , beating expectations by +18.95%.
Earnings released on 23 Feb 2023
EPS came in at -$0.56 surpassing the estimated -$0.71 by +21.13%, while revenue for the quarter reached $253.00k , missing expectations by -6.79%.
Earnings released on 3 Nov 2022
EPS came in at -$0.76 falling short of the estimated -$0.71 by -7.04%, while revenue for the quarter reached $344.00k , missing expectations by -80.89%.
Earnings released on 4 Aug 2022
EPS came in at -$0.71 falling short of the estimated -$0.62 by -14.52%, while revenue for the quarter reached $365.00k , missing expectations by -82.48%.
Earnings released on 5 May 2022
EPS came in at -$0.61 surpassing the estimated -$0.63 by +3.17%, while revenue for the quarter reached $419.00k , beating expectations by +151.40%.
Earnings released on 24 Feb 2022
EPS came in at $0.36 surpassing the estimated -$0.60 by +160.00%, while revenue for the quarter reached $567.00k , missing expectations by -85.23%.
Earnings released on 10 Nov 2021
EPS came in at -$0.66 falling short of the estimated -$0.65 by -1.54%, while revenue for the quarter reached $666.00k , beating expectations by +1.56%.
Earnings released on 12 Aug 2021
EPS came in at -$2.10 falling short of the estimated -$0.48 by -337.50%, while revenue for the quarter reached $844.00k , meeting expectations.
RLAY Stock Performance
Access detailed RLAY performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
